PAM
RGLS

Paradigm Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Paradigm Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-286
Closed -$323K – 840
2013
Q3 		$323K Buy
+286
New +$337K 0.05% 399

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paradigm Asset Management's RGLS Position: Q4 2013 in Review

Paradigm Asset Management sold out of Regulus Therapeutics (RGLS) in Q4 2013, closing a stake of 286 shares — an estimated $323K sold.

Paradigm Asset Management first reported a position in RGLS in Q3 2013 and held it in 1 quarter. The position peaked at $323K in Q3 2013. 49 funds tracked by Wall St. Rank hold RGLS as of Q4 2013.

  • Paradigm Asset Management reported no remaining Regulus Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Paradigm Asset Management sold 286 Regulus Therapeutics shares in Q4 2013, an estimated $323K.
  • Paradigm Asset Management first reported a position in Regulus Therapeutics in Q3 2013 and held it in 1 quarter.
  • Paradigm Asset Management's Regulus Therapeutics position peaked at $323K in Q3 2013.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2013.

Based on Paradigm Asset Management's 13F filing for Q4 2013, filed 7 Feb 2014.